

## MT2023-27: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- at least 18 years of age - confirmed, locally advanced or metastatic cancers that can not be treated surgically - unable to do strenuous activity but can walk and is able to do light work such as house work, office work

---

**Exclusion Criteria:**

- history of an autoimmune disease - major surgery or traumatic injury within 8 weeks before the first dose of the study medication - unhealed wounds from surgery or injury - ongoing or active infection - contact study staff for additional requirements

### Conditions & Interventions

**Interventions:**

Drug: TAK-280

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), Unresectable Locally Advanced or Metastatic Cancer

### More Information

**Description:** This is an early study of TAK-280 for people diagnosed with a type of cancer that cannot be treated or removed by surgery and the tumor is growing or has spread during or after other standard cancer treatment.

**Study Contact:** Nicholas Zorko - zorko004@umn.edu

**Principal Investigator:** Nicholas Zorko

**IRB**

**Number:** STUDY00019687

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.